Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 143

Sort by

Sort Order Select

Journal Articles

Non-White and Hispanic Patients Have Significantly Longer Time from Intent to CAR T Infusion (“Brain-to-Vein” Time) in Multiply Relapsed Diffuse Large B Cell Lymphoma

Neela Easwar, Anna Alperovich, Alexandra Gomez-Arteaga, Sebastian A. Mayer, Nora Chokr, Adrienne A. Phillips, Jingmei Hsu, Koen van Besien, Matthew Gromowsky, Matthew Lunning, Tsiporah B. Shore, Juliet N Barker, Samuel Yamshon

Blood (2024) 144 (Supplement 1): 2351.

https://doi.org/10.1182/blood-2024-201337

Published: 2024

Journal Articles

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Changchun Deng, Paolo F. Caimi, Umar Farooq, Nethrie Idippily, Maria Florencia Giraudo, Jane S. Reese, Sarah Kleinsorge-Block, Daniel Caley, Ryan Stadel, Koen van Besien, Marcos de Lima, Arun Kumar Arunachalam, J. Joseph Melenhorst, David Wald

Blood (2024) 144 (Supplement 1): 94.

https://doi.org/10.1182/blood-2024-206596

Published: 2024

Journal Articles

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

Nikki Agarwal, Pingfu Fu, Michael Daunov, Brenda W Cooper, Ben K. Tomlinson, Rebecca B. Klisovic, Marcos de Lima, Folashade Otegbeye, Changchun Deng, Yeritza Hernandez-Collazo, Jignesh Dalal, James Martin, Seunghee Margevicius, James J. Ignatz-Hoover, Ok-Kyong Chaekal, Molly Megan Gallogly, Koen van Besien, Leland Metheny

Blood (2024) 144 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2024-210550

Published: 2024

Journal Articles

A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy

Michael Daunov, John Sumodi, Nikki Agarwal, Molly Megan Gallogly, Leland Metheny, Ben K. Tomlinson, Rebecca B. Klisovic, Ali W. Bseiso, Brett Glotzbecker, Kord Honda, Koen van Besien

Blood (2024) 144 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2024-212304

Published: 2024

Journal Articles

Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models

Simona Pagliuca, Carmelo Gurnari, Arda Durmaz, Ashwin Kishtagari, Zain Virk, Lukasz P. Gondek, Matthew Guo, Maria Bettinotti, Mark B Juckett, Qing Cao, Suresh Kumar Balasubramanian, Vikram Dhillon, Ben K. Tomlinson, Koen van Besien, Alice Aarnink, Marie Thérèse Rubio, Valeria Visconte, Jaroslaw Maciejewski

Blood (2024) 144 (Supplement 1): 927.

https://doi.org/10.1182/blood-2024-210565

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Blood (2024) 144 (Supplement 1): 887.

https://doi.org/10.1182/blood-2024-200339

Published: 2024

Journal Articles

Low Dose Total Body Irradiation Improves CD19 CAR-T Expansion, Persistence, and Trafficking, Leading to Enhanced Efficacy in Large B-Cell Lymphoma

Mohammad Alhomoud, Michelle Foley, Mayumi Sugita, Takahiro Yamazaki, Leandro Martinez, Samuel Yamshon, Alexandra Gomez-Arteaga, Paul Pagnini, Tsiporah B. Shore, Olivier Boyer, Renier Brentjens, Koen Van Besien, Lorenzo Galluzzi, Silvia Formenti, Jeremie Martinet, Monica L. Guzman

Blood (2023) 142 (Supplement 1): 1016.

https://doi.org/10.1182/blood-2023-185216

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

Impact of Graft Source [Cord Blood Supported By CD34+ Selected Cells (Haplo-Cord) Vs. Matched Donor] on Transplant Outcomes in Myelofibrosis

Nima Ghalehsari, Zhengming Chen, Sebastian A. Mayer, Ghaith Abu-Zeinah, Tsiporah B. Shore, Ellen K. Ritchie, Richard T. Silver, Andrew I. Schafer, Joseph M. Scandura, Gail J. Roboz, Koen Van Besien, Alexandra Gomez-Arteaga

Blood (2023) 142 (Supplement 1): 6953.

https://doi.org/10.1182/blood-2023-185075

Published: 2023

Journal Articles

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Blood (2023) 142 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2023-173441

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Brenda W Cooper, Molly Megan Gallogly, Leland Metheny, Rebecca B. Klisovic, Kirsten Marie Boughan, Jane Reese Koc, Darong Wu, Changchun Deng, Koen Van Besien, Rose Tupta, Dina Schneider, Lisa Ciarrone, Marcos de Lima, Paolo F. Caimi, Benjamin K. Tomlinson

Blood (2023) 142 (Supplement 1): 6872.

https://doi.org/10.1182/blood-2023-191153

Published: 2023

Journal Articles

Development and Clinical Validation of an Ultra-Fast CAR-T Manufacturing Platform Enabling Production of CAR-T Cells in Less Than 1 Day

Ryan Stadel, Nethrie Idippily, Maria Florencia Giraudo, Paolo Caimi, Koen Van Besien, James Martin, John Wu, Changchun Deng, David Wald

Blood (2023) 142 (Supplement 1): 4848.

https://doi.org/10.1182/blood-2023-188214

Published: 2023

Journal Articles

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Blood (2023) 141 (18): 2194–2205.

https://doi.org/10.1182/blood.2022018254

Published: 2023

Includes: Supplemental data

Journal Articles

Low-Dose Radiation Improves Anti-CD19 CAR T-Cells Efficacy in Diffuse Large B-Cell Lymphoma through Fas/FasL Pathway

Mohammad Alhomoud, Jeremie Martinet, Mayumi Sugita, Takahiro Yamazaki, Olivier Boyer, Lorenzo Galluzzi, Silvia C Formenti, Koen Van Besien, Monica L. Guzman

Blood (2022) 140 (Supplement 1): 4519–4520.

https://doi.org/10.1182/blood-2022-169356

Published: 2022

Journal Articles

Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial

Mohammad Alhomoud, Usama Gergis, Adrienne A. Phillips, Jingmei Hsu, Zhengming Chen, Alexandra Gomez-Arteaga, Tsiporah B. Shore, Joseph Scandura, Koen Van Besien, Sebastian A. Mayer

Blood (2022) 140 (Supplement 1): 7583–7584.

https://doi.org/10.1182/blood-2022-170097

Published: 2022

Journal Articles

Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 4588–4589.

https://doi.org/10.1182/blood-2022-165311

Published: 2022

Journal Articles

Impact of Peri-Transplant Molecular Mutations on Outcomes of AML Patients Undergoing Fludarabine/Melphalan Conditioned Allogeneic Stem Cell Transplant

Mateo Mejia Saldarriaga, Yassine Tahri, Sangmin Lee, Zhengming Chen, Tsiporah B. Shore, Danielle Guarneri, Sebastian A. Mayer, Adrienne A. Phillips, Alexandra Gomez-Arteaga, Pinkal Desai, Ellen Ritchie, Michael B. Samuel, Gail J. Roboz, Koen van Besien, Jingmei Hsu

Blood (2021) 138 (Supplement 1): 4833.

https://doi.org/10.1182/blood-2021-149297

Published: 2021

Journal Articles

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

Bijal D. Shah, Caron Jacobson, Scott R. Solomon, Nitin Jain, Mark C. Johnson, Monika Vainorius, Lou Yu, Christopher R. Heery, Alan F. List, Fiona He, Ran Reshef, Luke P. Akard, Craig S. Sauter, Adam J. Olszewski, Abhinav Deol, Koen van Besien

Blood (2021) 138 (Supplement 1): 302.

https://doi.org/10.1182/blood-2021-150609

Published: 2021

NARROW

Non-White and Hispanic Patients Have Significantly Longer Time from Intent to CAR T Infusion (“Brain-to-Vein” Time) in Multiply Relapsed Diffuse Large B Cell Lymphoma

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy

Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Low Dose Total Body Irradiation Improves CD19 CAR-T Expansion, Persistence, and Trafficking, Leading to Enhanced Efficacy in Large B-Cell Lymphoma

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Impact of Graft Source [Cord Blood Supported By CD34+ Selected Cells (Haplo-Cord) Vs. Matched Donor] on Transplant Outcomes in Myelofibrosis

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Development and Clinical Validation of an Ultra-Fast CAR-T Manufacturing Platform Enabling Production of CAR-T Cells in Less Than 1 Day

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Low-Dose Radiation Improves Anti-CD19 CAR T-Cells Efficacy in Diffuse Large B-Cell Lymphoma through Fas/FasL Pathway

Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial

Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

Impact of Peri-Transplant Molecular Mutations on Outcomes of AML Patients Undergoing Fludarabine/Melphalan Conditioned Allogeneic Stem Cell Transplant

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only